My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    MG-132(R)
    MG-132(R)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0559
    CAS #: 1211877-36-9Purity ≥98%

    Description: MG-132 (R) (R-isomer of MG-132), a peptide aldehyde, is a novel, potent, non-specific, cell permeable and reversible inhibitor 20S proteasome inhibitor, with IC50 of 24.2 nM for the β5 chymotrypsin-like active site. It can inhibit proteasome activity in lysates of J558L multiple myeloma cells and EMT6 breast cancer cells. In comparison to (S)-MG132, the (R)-MG132 stereoisomer is a more effective inhibitor of chymotrypsin-like (ChTL), trypsin-like (TL), and peptidylglutamyl peptide hydrolyzing proteasome (PGPH) activities. 

    References: J Med Chem. 2010;53(4):1509-18; J Biol Chem. 2005;280(31):28394-401; Oncol Rep. 2009;22(1):215-21.

    Related CAS: 133407-82-6 (MG-132)


    Publications Citing Use of InvivoChem MG-132Eur J Med Chem. 2020 May 5;199:112377

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)475.62
    FormulaC26H41N3O5
    CAS No.1211877-36-9
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 95 mg/mL (199.7 mM)
    Water: <1 mg/mL
    Ethanol: 95 mg/mL (199.7 mM)
    Solubility (In vivo) 4% DMSO+30% PEG 300+20% propylene glycol+ddH2O: 2 mg/mL
    Synonyms R-isomer of MG-132; MG132; MG 132; (R)-MG 132; (R)-MG-132; (R)-MG132 

    Chemical Name: benzyl ((S)-4-methyl-1-(((S)-4-methyl-1-(((S)-4-methyl-1-oxopentan-2-yl)amino)-1-oxopentan-2-yl)amino)-1-oxopentan-2-yl)carbamate

    InChi Key: TZYWCYJVHRLUCT-VABKMULXSA-N

    InChi Code: InChI=1S/C26H41N3O5/c1-17(2)12-21(15-30)27-24(31)22(13-18(3)4)28-25(32)23(14-19(5)6)29-26(33)34-16-20-10-8-7-9-11-20/h7-11,15,17-19,21-23H,12-14,16H2,1-6H3,(H,27,31)(H,28,32)(H,29,33)/t21-,22-,23-/m0/s1

    SMILES Code: O=C(OCC1=CC=CC=C1)N[[email protected]@H](CC(C)C)C(N[[email protected]@H](CC(C)C)C(N[[email protected]@H](CC(C)C)C=O)=O)=O


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: (R)-MG132 is a potent, cell permeable and reversible inhibitor of proteasomes. It can inhibit proteasome activity in lysates of J558L multiple myeloma cells and EMT6 breast cancer cells. In comparison to (S)-MG132, the (R)-MG132 stereoisomer is a more effective inhibitor of chymotrypsin-like (ChTL), trypsin-like (TL), and peptidylglutamyl peptide hydrolyzing proteasome (PGPH) activities. However, (R)-MG132, despite being the most effective inhibitor, having a 5-fold lower IC50 than MG-132 (0.22 μM versus 0.89 μM) does not exert stronger cytostatic/cytotoxic effects against tumor cells.


    Kinase Assay: After growing on six-well plates (3×105 cells/well) for 24 h, C6 glioma cells are treated with either PBS (control) or 18.5 μM MG-132 for 3, 6, 12, or 24 h at 37°C. Cells are thoroughly scraped from the culture dishes with a cell scraper and washed with cold PBS. After centrifugation for 10 min at 800×g, the cell pellets are suspended in ice-cold buffer (50 mM Tris-HCl, pH 7.5, 20 μM ATP, 5 mM MgCl2, 1 mM dithiothreitol, and 20% glycerol) and homogenized with a Pyrex glass microhomogenizer (20 strokes). The homogenate is centrifuged at 15 000×g for 10 min at 4°C to obtain supernatant. Protein concentration is determined using protein assay kits. A total of 10 μL (1 μg/μL) of each freshly made supernatant is incubated in a 96-well plate at 37°C for 30 min with 10 μL of 300 μM of Succinyl-LLVY-AMC and 85 μL of assay buffer (20 mM Tris-HCl, pH 7.5, and 20% glycerol). Release of fluorescent AMC is measured with a spectrofluorometer at 440 nm with an excitation wavelength of 380 nm.


    Cell Assay: The cytostatic/cytotoxic effects in EMT6 cells are measured using crystal violet staining. Briefly, tumor cells are dispensed into 96-well plates at 1.5 × 103 cells per well and allowed to attach overnight. The following day the investigated agents are added at indicated concentrations. After 24 h of incubation the cells are rinsed with PBS and stained with 0.5% crystal violet in 2% ethanol for 10 min at room temperature. Next, plates are washed four times with tap water and cells are lysed with 1% SDS solution. Absorbance is measured at 595 nm using an ELISA reader. The cytostatic/cytotoxic effects in J588L cells are measured using standard MTT assay. Briefly, tumor cells are dispensed into 96-well plates at 3 × 103 cells per well. The following day the investigated agents are added at indicated concentrations. MTT solution at a concentration of 1 mg/mL is added to each well for the last 4 h of incubation. Then the cells are lysed using resuspension buffer containing SDS (0.2 g/mL) and DMF (0.5 mL/mL) at pH 4.7 and left overnight in the incubator. On the following day the absorbance is measured at 570 nm using an ELISA reader.

    In VivoThe in vivo antitumor activity of MG-132 against cervical cancer is examined using s.c. xenograft models. MG-132 is injected at 1 mg/kg using the following schedule: days 1, 4, 8, 12, 15 18, 23, and 26 for mice bearing HeLa tumors. The growth inhibition rates of MG132 compared to control is 49%. MG-132 (i.p., 0.1 mg/kg/day) attenuates pressure-overload-induced cardiac hypertrophy and improves cardiac function in abdominal aortic banding (AAB) rats through regulation of ERK1/2 and JNK1 signaling pathways.
    Animal model

    Mice: C.B-17/lcr-scid/scidJcl mice are inoculated s.c. with HeLa, CaSki, or C33A (1×107 cells). Tumors are allowed to grow for 1 week. Mice are killed and tumors are removed. Tumors are then cut into 2-mm diameter pieces and s.c. transplanted in C.B-17/lcr-scid/scidJcl mice (n=6 per group). One week after inoculation, mice are treated with i.v. injection of saline (control), MG-132 (1 mg/kg/dose) twice a week for 4 weeks. The volume (V) of tumors is measured before every injection, as estimated using equation V=a×b2/2 where a and b are major and minor axes of the tumor measured by a caliper, respectively. Rat: Male Sprague-Dawley rats (8 weeks old, 180-230 g) are used to establish pressure-overload model. All animals are separated into four groups (10 rats per group): (i) vehicle-treated sham group; (ii) MG-132-treated sham group; (iii) vehicle-treated abdominal aortic banding (AAB) group; and (iv) MG-132-treated AAB group. Under intraperitoneal pentobarbital (50 mg/kg) anesthesia, AAB is created using a 5-0 suture tied twice around the abdominal aorta in which a 21-gauge needle is inserted. The needle is then retracted yielding a 70-80% constriction with an outer aortic diameter of ~0.8 mm. In the sham surgery rats, the same surgery is performed except the aorta is constricted. At Day 3 after the surgery, MG-132-treated rats are intraperitoneally injected with 0.1 mg/kg/day of MG-132 for 8 weeks. All control animals are injected with a corresponding volume of vehicle only (0.1% DMSO).

    Formulation & DosageMG-132 is dissolved in vehicle (saline) (Mice) or vehicle (0.1% DMSO) (Rat)
    References

    J Med Chem. 2010;53(4):1509-18; J Biol Chem. 2005;280(31):28394-401; Oncol Rep. 2009;22(1):215-21.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

     

    MG-132(R)

     

    MG-132(R)

    MG-132(R)


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?